Edinburgh-based medical device developer 1nhaler has raised £2.2 million in follow-on funding led by Archangels, with participation from Scottish Enterprise and BBB Investments. The investment will support the development and clinical testing of the company’s single-dose dry powder inhaler technology ahead of a planned regulatory submission.
Founded in 2017 by Don Smith and Lisa McMyn, who serves as CEO, 1nhaler develops a compact inhaler designed to deliver medicines in dry powder form. Its single-use device is made predominantly from cardboard and folds from a flat, credit-card-sized format into a three-dimensional inhaler. The propellant-free design incorporates a patented membrane-based drug delivery system.
The company’s lead product, 1nhaler Salbutamol, combines its inhaler platform with salbutamol, an established medicine used to treat asthma symptoms.
The new funding will support the transfer of 1nhaler Salbutamol to a contract manufacturer for the production of clinical trial materials. The company also plans to conduct a small clinical study to support a regulatory filing targeted for late 2027.
Part of the investment will fund a manufacturing engineering study with Harro Höfliger to assess commercial-scale production of the inhaler. Additional resources will support business development discussions with prospective pharmaceutical partners.
1nhaler is developing its platform for applications beyond asthma treatment, with potential uses across other respiratory conditions and additional medicines suitable for inhaled delivery. The company aims to address challenges associated with conventional inhalers, including portability, manufacturing costs and environmental impact.
The latest financing follows a £1.5 million seed funding announcement in November 2025, also backed by Archangels, Scottish Enterprise and BBB Investments. That earlier investment was directed towards clinical development and manufacturing preparation.
